{
    "organizations": [],
    "uuid": "7045578a3458791cc29730bd1f35c864caf043cc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-terns-pharma-acquires-global-exclu/brief-terns-pharma-acquires-global-exclusive-rights-to-develop-and-commercialize-three-nash-assets-from-lilly-idUSASC09UUB",
    "ord_in_thread": 0,
    "title": "BRIEF-Terns Pharma Acquires Global, Exclusive Rights To Develop And Commercialize Three NASH Assets From Lilly",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - Eli Lilly and Co:\n* TERNS PHARMACEUTICALS ACQUIRES GLOBAL, EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE THREE NASH ASSETS FROM LILLY\n* VALIDATED NASH TARGET * DEVELOPMENT OF CLINICAL PROGRAMS WILL FOCUS ON REGULATORY APPROVAL IN CHINA AND ADDITIONAL GLOBAL MARKETS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-04T18:10:00.000+03:00",
    "crawled": "2018-04-04T13:21:43.021+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "eli",
        "lilly",
        "co",
        "tern",
        "pharmaceutical",
        "acquires",
        "global",
        "exclusive",
        "right",
        "develop",
        "commercialize",
        "three",
        "nash",
        "asset",
        "lilly",
        "validated",
        "nash",
        "target",
        "development",
        "clinical",
        "program",
        "focus",
        "regulatory",
        "approval",
        "china",
        "additional",
        "global",
        "market",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}